pyruvate kinase inhibitors (Allos)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namepyruvate kinase inhibitors (Allos)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHemoglobins modulatorsPyruvate kinase inhibitors
TargetsPyruvate kinaseHemoglobins
Therapy Area/IndicationsPeripheral Vascular DiseasesAngina Pectoris
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAllos Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAllos Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsPeripheral Vascular DiseasesAngina Pectoris

Other Information

ATC CodeN/A
Related LinksN/A